1. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340(6): 448–454. Erratum in N Engl J Med 1999; 340(17):1376.
2. McEver RP. Adhesive Interactions of Leukocytes, Platelets, and the Vessel Wall during Hemostasis and Inflammation. Thromb Haemost 2001; 86(3): 746–756.
3. Johnson K, Aarden L, Choi Y et al. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 1996; 87(12): 5051–5060.
4. Stouthard JML, Levi M, Hack CE et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76(5): 738–742.
5. Levi M, van der Poll T, ten Cate H et al. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 1997; 27(1): 3–9.
6. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107(3): 398–404.
7. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011; 106(4): 713–718.
8. Yuhara H, Steinmaus C, Corley D et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37(10): 953–962.
9. Bernstein CN, Blanchard JF, Houston DS et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85(3): 430–434.
10. Kappelman MD, Horvath-Puho E, Sandler RS et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60(7): 937–943.
11. Miehsler W, Reinisch W, Valic E et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53(4): 542–548.
12. Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 2000; 35(6): 619–623.
13. Novacek G, Weltermann A, Sobala A et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139(3): 779–787.
14. Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can J Gastroenterol 2007; 21(8): 507–511.
15. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103(9): 2272–2280.
16. Merrill A, Millham F. Increased Risk of Postoperative Deep Vein Thrombosis and Pulmonary Embolism in Patients With Inflammatory Bowel Disease: A Study of National Surgical Quality Improvement Program Patients. Arch Surg 2012; 147(2): 120–124.
17. Nguyen GC, Boudreau H, Harris ML et al. Outcomes of Obstetric Hospitalizations Among Women With Inflammatory Bowel Disease in the United States. Clin Gastroenterol Hepatol 2009; 7(3): 329–334.
18. Bröms G, Granath F, Linder M et al. Complications from inflammatory bowel disease during pregnancy and delivery. Clin Gastroenterol Hepatol 2012; 10(11): 1246–1252.
19. Heit JA, Kobbervig CE, James AH et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143(10): 697–706.
20. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375(9715): 657–663.
21. Solem CA, Loftus EV, Tremaine WJ et al. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99(1): 97–101.
22. Van Bodegraven AA, Schoorl M, Linskens RK et al. Persistent activation of coagulation and fibrinolysis after treatment of active ulcerative colitis. Eur J Gastroenterol Hepatol 2002; 14(4): 413–418.
23. Johns DR. Cerebrovascular complications of inflammatory bowel disease. Am J Gastroenterol 1991; 86(3): 367–370.
24. Keyser BJ, Hass AN. Retinal vascular disease in ulcerative colitis. Am J Ophthalmol 1994; 118(3): 395–396.
25. Hatoum OA, Spinelli KS, Abu-Hajir M et al. Mesenteric venous thrombosis in inflammatory bowel disease. J Clin Gastroenterol 2005; 39(1): 27–31.
26. Younes-Mhenni S, Derex L, Berruyer M et al. Large-artery stroke in a young patient with Crohn’s disease. Role of vitamin B6 deficiency-induced hyperhomocysteinemia. J Neurol Sci 2004; 221(1–2): 113–115.
27. Levy PJ, Tabares AH, Olin JW. Lower extremity arterial occlusions in young patients with Crohn’s colitis and premature atherosclerosis: report of six cases. Am J Gastroenterol 1997; 92(3): 494–497.
28. Di Fabio F, Obrand D, Satin R et al. Intra-abdominal venous and arterial thromboembolism in inflammatory bowel disease. Dis Colon Rectum 2009; 52(2): 336–342.
29. Mutlu B, Ermeydan CMH, Enç F et al. Acute myocardial infarction in a young woman with severe ulcerative colitis. Int J Cardiol 2002; 83(2): 183–185.
30. Zitomersky NL, Verhave M, Trenor CC. Thrombosis and inflammatory bowel disease: A call for improved awareness and prevention. Inflamm Bowel Dis 2011; 17(1): 458–470.
31. Jackson LM, O’Gorman PJ, O’Connell J et al. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 1997; 90(3): 183–188.
32. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131(4): 417–430.
33. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20(10): 2322–2328.
34. Parry GC, Mackman N. NF-κB Mediated Transcription in Human Monocytic Cells and Endothelial Cells. Trends Cardiovasc Med 1998; 8(3): 138–142.
35. Chen Y, Wang J, Yao Y et al. CRP regulates the expression and activity of tissue factor as well as tissue factor pathway inhibitor via NF-kappaB and ERK 1/2 MAPK pathway. FEBS Lett 2009; 583(17): 2811–2818.
36. Chen C, Nan B, Lin P et al. C-reactive protein increases plasminogen activator inhibitor-1 expression in human endothelial cells. Thromb Res 2008; 122(1): 125–133.
37. Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arter Thromb Vasc Biol 2005; 25(10): 2216–2221.
38. Bisoendial RJ, Kastelein JJP, Levels JHM et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96(7): 714–716.
39. Hein TW, Singh U, Vasquez-Vivar J et al. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis 2009; 206(1): 61–68.
40. Hudson M, Chitolie A, Hutton RA et al. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996; 38(5): 733–737.
41. Kume K, Yamasaki M, Tashiro M et al. Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis. Intern Med 2007; 46(17): 1323–1329.
42. Zezos P, Papaioannou G, Nikolaidis N et al. Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation. World J Gastroenterol 2005; 11(48): 7639–7345.
43. Smith CJ, Haire WD, Kaufman SS et al. Determination of prothrombin activation fragments in young patients with inflammatory bowel disease. Am J Gastroenterol 1996; 91(6): 1221–1225.
44. Chamouard P, Grunebaum L, Wiesel ML et al. Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995; 7(12): 1183–1188.
45. Chiarantini E, Valanzano R, Liotta AA et al. Hemostatic abnormalities in inflammatory bowel disease. Thromb Res 1996; 82(2): 137–146.
46. Souto JC, Martínez E, Roca M et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995; 40(9): 1883–1889.
47. Saibeni S, Vecchi M, Valsecchi C et al. Reduced free protein S levels in patients with inflammatory bowel disease: Prevalence, clinical relevance, and role of anti-protein S antibodies. Dig Dis Sci 2001; 46(3): 637–643.
48. Koutroubakis IE, Sfiridaki A, Mouzas IA et al. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95(1): 190–194.
49. Faioni EM, Ferrero S, Fontana G et al. Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. Crit Care Med 2004; 32(5 Suppl): S266-S270.
50. Lorenz R, Olbert P, Born P. Factor XIII in chronic inflammatory bowel diseases. Semin Thromb Hemost 1996; 22(5): 451–455.
51. Andoh A, Tsujikawa T, Hata K et al. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol 2005; 100(9): 2042–2048.
52. Saibeni S, Bottasso B, Spina L et al. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol 2004; 99(10): 1966–1970.
53. Heits F, Stahl M, Ludwig D et al. Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease. J Interferon Cytokine Res 1999; 19(7): 757–760.
54. Collins CE, Rampton DS, Rogers J et al. Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997; 9(12): 1213–1217.
55. Collins CE, Cahill MR, Newland AC et al. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994; 106(4): 840–845.
56. Danese S, Katz JA, Saibeni S et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003; 52(10): 1435–1441.
57. Menchén L, Marín-Jiménez I, Arias-Salgado EG et al. Matrix metalloproteinase 9 is involved in Crohn’s disease-associated platelet hyperactivation through the release of soluble CD40 ligand. Gut 2009; 58(7): 920–928.
58. Sawada-Hase N, Kiyohara T, Miyagawa J et al. An increased number of CD40-high monocytes in patients with Crohn’s disease. Am J Gastroenterol 2000; 95(6): 1516–1523.
59. Power CA, Clemetson JM, Clemetson KJ et al. Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine 1995; 7(6): 479–482.
60. Irving PM, Macey MG, Shah U et al. Formation of platelet-leukocyte aggregates in inflammatory bowel disease. Inflamm Bowel Dis 2004; 10(4): 361–372.
61. Boehme MW, Autschbach F, Zuna I et al. Elevated serum levels and reduced immunohistochemical expression of thrombomodulin in active ulcerative colitis. Gastroenterology 1997; 113(1): 107–117.
62. Meucci G, Pareti F, Vecchi M et al. Serum von Willebrand factor levels in patients with inflammatory bowel disease are related to systemic inflammation. Scand J Gastroenterol 1999; 34(3): 287–290.
63. Papa A, Scaldaferri F, Danese S et al. Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. Dig Dis 2008; 26(2): 149–155.
64. Hatoum OA, Binion DG, Otterson MF et al. Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology 2003; 125(1): 58–69.
65. Horowitz S, Binion DG, Nelson VM et al. Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2007; 292(5): G1323-G1336.
66. Lancellotti S, De Filippis V, Pozzi N et al. Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med 2010; 48(3): 446–456.
67. Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2010; 16(1): 52–57.
68. Van De Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004; 24(8): 1374–1383.
69. Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112(1): 19–27.
70. Guédon C, Le Cam-Duche V, Lalaude O et al. Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. Am J Gastroenterol 2001; 96(5): 1448–1454.
71. Koutroubakis IE, Sfiridaki A, Tsiolakidou G et al. Genetic risk factors in patients with inflammatory bowel disease and vascular complications: case-control study. Inflamm Bowel Dis 2007; 13(4): 410–415.
72. Bernstein CN, Sargent M, Vos HL et al. Mutations in clotting factors and inflammatory bowel disease. Am J Gastroenterol 2007; 102(2): 338–343.
73. Liebman HA, Kashani N, Sutherland D et al. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Gastroenterology 1998; 115(4): 830–834.
74. Zhong M, Dong XW, Zheng Q et al. Factor v Leiden and thrombosis in patients with inflammatory bowel disease (IBD): A meta-analysis. Thromb Res 2011; 128(5): 403–409.
75. Liang J, Wu S, Feng B et al. Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis. J Gastroenterol 2011; 46(10): 1158–1166.
76. Vecchi M, Sacchi E, Saibeni S et al. Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis. Dig Dis Sci 2000; 45(7): 1465–1469.
77. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: A meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3(2): 292–299.
78. Dawson S, Hamsten A, Wiman B et al. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11(1): 183–190.
79. Stegnar M, Uhrin P, Peternel P et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: Relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998; 79(5): 975–979.
80. Heliö T, Wartiovaara U, Halme L et al. Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34(2): 170–174.
81. Yurekli BPS, Aksoy DY, Aybar M et al. The search for a common thrombophilic state during the active state of inflammatory bowel disease. J Clin Gastroenterol 2006; 40(9): 809–813.
82. Humphrey LL, Fu R, Rogers K et al. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008; 83(11): 1203–1212.
83. den Heijer M, Rosendaal FR, Blom HJ et al. Hyperhomocysteinemia and venous thrombosis: A meta-analysis. Thromb Haemost 1998; 80(6): 874–877.
84. Oussalah A, Guéant JL, Peyrin-Biroulet L. Meta-analysis: Hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther 2011; 34(10): 1173–1184.
85. Koutroubakis IE, Petinaki E, Anagnostopoulou E et al. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci 1998; 43(11): 2507–2512.
86. Saibeni S, Ciscato C, Vecchi M et al. Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis. J Thromb Haemost 2006; 4(7): 1510–1516.
87. Carty E, MacEy M, Rampton DS. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14(9): 1169–1179.
88. Fägerstam JP, Whiss PA, Ström M et al. Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease. Inflamm Res 2000; 49(9): 466–472.
89. Johannesdottir SA, Horváth-Puhó E, Dekkers OM et al. Use of Glucocorticoids and Risk of Venous Thromboembolism: A Nationwide Population-Based Case-Control Study. JAMA Intern Med 2013; 173(9): 743–752.
90. Małyszko J, Małyszko JS, Takada A et al. Effects of immunosuppressive drugs on platelet aggregation in vitro. Ann Transplant 2002; 7(1): 55–68.
91. Hommes DW, van Dullemen HM, Levi M et al. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn’s disease. Haemostasis 1997; 27(6): 269–277.
92. Danese S, Sans M, Scaldaferri F et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn’s disease. J Immunol 2006; 176(4): 2617–2624.
93. Chamouard P, Desprez D, Hugel B et al. Circulating cell-derived microparticles in Crohn’s disease. Dig Dis Sci 2005; 50(3): 574–580.
94. Vereckei E, Krivan G, Reti M et al. Anti-TNF-alpha-induced anti-phospholipid syndrome manifested as necrotizing vasculitis. Scand J Rheumatol 2010; 39(2): 175–177.
95. Davies R, Galloway JB, Watson KD et al. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70(10): 1831–1834.
96. Lorenz R, Born P, Olbert P et al. Factor XIII substitution in ulcerative colitis. Lancet 1995; 345(8947): 449–450.
97. Oshitani N, Nakamura S, Matsumoto T et al. Treatment of Crohn’s disease fistulas with coagulation factor XIII. Lancet 1996; 347(8994): 119–120.
98. Bregenzer N, Caesar I, Andus T et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. The Factor XIII Study Group. Z Gastroenterol 1999; 37(10): 999–1004.
99. Shen J, Ran ZH, Tong JL et al. Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther 2007; 26(5): 653–663.
100. Chande N, McDonald JW, MacDonald JK et al. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010; (10): CD006774. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD006774.pub3>.
101. Huerta C, Johansson S, Wallander MA et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167(9): 935–943.
102. van der Woude CJ, Kolacek S, Dotan I et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010; 4(5): 493–510.
103. Kvasnička J. Primární antitrombotická prevence žilní trombózy ve vnitřním lékařství. Vnitř Lék 2005; 51(7–8): 781–789.
104. Kornbluth A, Sachar DB Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105(3): 501–523. Erratum in Am J Gastroenterol 2010; 105(3): 500.
105. Mowat C, Cole A, Windsor A et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60(5): 571–607.
106. Van Assche G, Dignass A, Reinisch W et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations. J Crohns Colitis 2010; 4(1): 63–101.
107. Van Assche G, Dignass A, Bokemeyer B et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013; 7(1): 1–33.
108. Leizorovicz A, Cohen AT, Turpie AG et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110(7): 874–879.
109. Samama MM, Cohen AT, Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341(11): 793–800.
110. Aryal K, Al-Khaffaf H. Venous thromboembolic complications following air travel: what’s the quantitative risk? A literature review. Eur J Vasc Endovasc Surg 2006; 31(2): 187–199.
111. Tinsley A, Naymagon S, Trindade AJ et al. A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol 2013; 47(1): e1-e6. Dostupné z DOI: <http://dx.doi.org/10.1097/MCG.0b013e31824c0dea>.
112. Koutroubakis IE. Therapy insight: Vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2(6): 266–272.
113. Qaseem A, Snow V, Barry P et al. Current diagnosis of venous thromboembolism in primary care: A clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Fam Med 2007; 5(1): 57–62.
114. Torbicki A, Perrier A, Konstantinides S et al. Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2008; 29(18): 2276–2315.
115. Tan VP, Chung A, Yan BP et al. Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol 2013; 28(7): 1095–1113.